Due to their practice-changing results on NSCLC, crizotinib, ceritinib, and alectinib were investigated also in lung NECs harboring ALK fusion, showing significant disease responses with manageable tolerability in several cases (about 7 partial responses on the 13 cases collected in a literature-based case series review) (47, 49, 51, 54). The gene discussed is ALK; the disease is non-small cell lung carcinoma.